Zai

Zai Lab Plants a Tree for Every Employee on Earth Day 2022

Retrieved on: 
Tuesday, April 19, 2022
Social, CEO, Carbon, Forest, Climate change, Corporate governance, Zai, NASDAQ, Doctor of Philosophy, Degenerative disease, GLOBE, Environmental, social and corporate governance, Patient, Tree, Workforce, SAN, Infection, Sustainability, Solution, Volunteering, Partnership, Health, C3, Renewable energy, Pharmaceutical industry

Planting a tree in honor of each one of our employees shows tangible appreciation for their contributions and more broadly helps reforestation efforts worldwide, said Jim Massey, Chief Sustainability Officer, Zai Lab.

Key Points: 
  • Planting a tree in honor of each one of our employees shows tangible appreciation for their contributions and more broadly helps reforestation efforts worldwide, said Jim Massey, Chief Sustainability Officer, Zai Lab.
  • As a young, vibrant and growing healthcare company, Zai Lab commits to Grow Green which means we are laying the groundwork for the sustainability of our business and our planet.
  • Samantha Du, Ph.D., Founder, Chairperson and CEO of Zai Lab, has already committed an additional $10,000 to the effort.
  • For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

Zai Lab Announces Upcoming Presentation at February Investor Conference

Retrieved on: 
Monday, February 7, 2022
NASDAQ, GLOBE, Degenerative disease, Zai, Health, Infection, Conference, SAN, Fine chemical

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conference in February:

Key Points: 
  • SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conference in February:
    Webcast link of the 11th Annual SVB Leerink Global Healthcare Conference will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 90 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Zai Lab Announces Upcoming Presentations at January Investor Conferences

Retrieved on: 
Wednesday, December 29, 2021
Zai, SAN, Health, GLOBE, Infection, Degenerative disease, NASDAQ, Conference, Fine chemical

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in January:

Key Points: 
  • SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in January:
    Webcast link of the 40th Annual J.P. Morgan Healthcare Conference will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 30 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

Retrieved on: 
Wednesday, December 22, 2021
U.S. Securities and Exchange Commission, Novartis, Drug development, Medicine, Transplant, Anesthesiology, Kidney, Acarbose, Patient, Immunity, Private Securities Litigation Reform Act, Coronavirus, Internal medicine, Infection, CEO, Medical Affairs Bureau, CMO, International development, Degenerative disease, Diabetes, NASDAQ, University, Senior, Forward-looking statement, Health, COVID-19, Autoimmunity, Faculty, Artemether/lumefantrine, Allergy, Yale school, Zai, Ciprofloxacin, SAN, Â, Risk, GLOBE, Pharmaceutical industry, Telbivudine, Daptomycin, Neuroscience

Dr. Reinhart has been with the company since inception, first as an advisor and since 2017, as Chief Medical Officer responsible for the autoimmune and infectious diseases portfolio.

Key Points: 
  • Dr. Reinhart has been with the company since inception, first as an advisor and since 2017, as Chief Medical Officer responsible for the autoimmune and infectious diseases portfolio.
  • Harald has played a pivotal role in building Zai Labs broad and deep pipeline in autoimmune, infectious diseases and neuroscience, said Dr. Samantha Du, Founder, Chairperson and CEO at Zai Lab.
  • This promotion not only recognizes Haralds tremendous contributions but will also empower him to further build a leading clinical team across these therapeutic areas.
  • He completed his medical and subspecialty training in the U.S. with board-certifications in internal medicine and infectious diseases.

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer

Retrieved on: 
Friday, December 3, 2021
Private Securities Litigation Reform Act, Patient, Ovarian cancer, Coronavirus, Safety, PARP, Niraparib, Risk, Disease, Forward-looking statement, Company, NORA, Woman, Health, Clinical trial, Progression-free survival, SAN, COVID-19, PFS, GSK, U.S. Securities and Exchange Commission, Death, Degenerative disease, Endometrial cancer, GLOBE, Adult, Cholangiocarcinoma, Infection, NRDL, Maintenance, ADP, Zai, NASDAQ, Peritonitis, Pharmaceutical industry, Medical imaging, Birth control, Online shopping

The inclusion of ZEJULA in the NRDL for first-line maintenance treatment of ovarian cancer is an important step in achieving that mission.

Key Points: 
  • The inclusion of ZEJULA in the NRDL for first-line maintenance treatment of ovarian cancer is an important step in achieving that mission.
  • We are grateful for this action by the NHSA to make ZEJULA more accessible to Chinese patients with ovarian cancer.
  • In December 2020, ZEJULA was included in the NRDL as a maintenance treatment of adult patients with platinum-sensitive, recurrent ovarian cancer.
  • New agents that prolong the duration of response following platinum-based treatment and delay the relapse of ovarian cancer will benefit patients with ovarian cancer inChina.

Zai Lab Announces Upcoming Presentations at December Investor Conferences

Retrieved on: 
Tuesday, November 23, 2021
Health, Infection, Degenerative disease, GLOBE, SAN, Conference, Zai, NASDAQ, Fine chemical

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in December:

Key Points: 
  • SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in December:
    Webcast link of the 4th Evercore ISI HealthCONx Conference will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • An archived replay will be available for 90 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China

Retrieved on: 
Tuesday, November 9, 2021
Health, Safety, Lung cancer, Cancer, BPMC, Science, Private Securities Litigation Reform Act, Pulmonary toxicity, SAN, U.S. Securities and Exchange Commission, SYMPHONY, NASDAQ, Degenerative disease, Disease, Security (finance), Coronavirus, Infection, Risk, Mutation, Goal, EGFR, COVID-19, Research, Zai, Forward-looking statement, HIV disease progression rates, Annual report, CNS, Twitter, GLOBE, Large-cell lung carcinoma, LinkedIn, T790M, NSCLC, SEC, Precision medicine, Central nervous system, Marketing, Patent, Patient, Drug development, Pharmaceutical industry

CAMBRIDGE, Mass., SHANGHAI and SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Blueprint Medicines Corporation (NASDAQ:BPMC) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Discovered by Blueprint Medicines, BLU-945 and BLU-701 are investigational next-generation EGFR inhibitors with first-in-class potential.

Key Points: 
  • Discovered by Blueprint Medicines, BLU-945 and BLU-701 are investigational next-generation EGFR inhibitors with first-in-class potential.
  • In addition, this collaboration enables opportunities to combine BLU-945 or BLU-701 with other Zai Lab lung cancer drug candidates to address off-target resistance mutations.
  • Derived from Blueprint Medicines' proprietary research platform, BLU-945 and BLU-701 are investigational next-generation EGFR non-covalent tyrosine kinase inhibitors.
  • Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Securities Exchange Act of 1934, Goldman Sachs, Safety, Drug development, Private Securities Litigation Reform Act, Therapy, Health, Clinical trial, U.S. Securities and Exchange Commission, Infection, Neuroscience, NASDAQ, Knowledge, Hospital, Coronavirus, Risk, Goal, COVID-19, KRTX, Schizophrenia, Securities Act of 1933, Zai, Forward-looking statement, Annual report, National Clinical Coding Qualification (UK), Lists of diseases, Psychosis, PANSS, Brain, D2, Karuna, Federal Lands Jobs and Energy Security Act, Capital University of Medical Sciences, Central nervous system, Patient, Psychiatry, M1, Degenerative disease, Fine chemical, Pharmaceutical industry, KarXT, Karuna Therapeutics, Zai Lab, KARXT, KARUNA THERAPEUTICS, ZAI LAB

Karuna is evaluating KarXT in late-stage clinical trials for the treatment of schizophrenia and psychosis in Alzheimers disease.

Key Points: 
  • Karuna is evaluating KarXT in late-stage clinical trials for the treatment of schizophrenia and psychosis in Alzheimers disease.
  • Zai Lab will work with Karuna to design the optimal strategy to accelerate the development and regulatory timeline of KarXT in Greater China.
  • Karuna is also eligible to receive up to $72 million in sales milestones and low-double-digit to high-teens tiered royalties based on annual net sales of KarXT in Greater China.
  • Zai Lab will fund substantially all development, regulatory, and commercialization activities in Greater China.

Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Retrieved on: 
Tuesday, November 9, 2021
Securities Exchange Act of 1934, Goldman Sachs, Safety, Drug development, Private Securities Litigation Reform Act, Therapy, Health, Clinical trial, SAN, U.S. Securities and Exchange Commission, Infection, Neuroscience, NASDAQ, Knowledge, Hospital, Coronavirus, Risk, Goal, COVID-19, KRTX, Schizophrenia, Zai, Securities Act of 1933, Forward-looking statement, Annual report, National Clinical Coding Qualification (UK), Lists of diseases, Psychosis, PANSS, GLOBE, Brain, D2, Federal Lands Jobs and Energy Security Act, Capital University of Medical Sciences, Central nervous system, Patient, Psychiatry, M1, Degenerative disease, Fine chemical, Pharmaceutical industry

BOSTON and SHANGHAI and SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced their entry into an exclusive license agreement for the development, manufacturing, and commercialization of KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

Key Points: 
  • Karuna is evaluating KarXT in late-stage clinical trials for the treatment of schizophrenia and psychosis in Alzheimers disease.
  • Zai Lab will work with Karuna to design the optimal strategy to accelerate the development and regulatory timeline of KarXT in Greater China.
  • Karuna is also eligible to receive up to $72 million in sales milestones and low-double-digit to high-teens tiered royalties based on annual net sales of KarXT in Greater China.
  • Zai Lab will fund substantially all development, regulatory, and commercialization activities in Greater China.

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Retrieved on: 
Thursday, November 4, 2021
Health, Conference, NASDAQ, SAN, GLOBE, Degenerative disease, Infection, Zai, Fine chemical, Animal

An archived replay will be available for 30 days following the event.

Key Points: 
  • An archived replay will be available for 30 days following the event.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease.
  • Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.
  • For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global .